About Dr. Shen Xizhong
Dr. Shen Xizhong (沈锡中) is a Professor, Doctoral Supervisor, and one of China's leading gastroenterologists and hepatologists, based at the Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine. With extensive clinical and research expertise in the management of chronic liver disease — including chronic hepatitis B, chronic hepatitis C, autoimmune liver diseases, non-alcoholic fatty liver disease (NAFLD/MASLD), and liver cirrhosis and its complications — as well as inflammatory bowel disease and other gastrointestinal conditions, Dr. Shen is recognized as a senior authority in gastroenterology and hepatology at one of Shanghai's most distinguished academic medical centers.
Chronic liver disease represents one of the most significant public health challenges in China, driven by the high prevalence of chronic hepatitis B infection — affecting approximately 70 million people in China — and the rapidly rising burden of non-alcoholic fatty liver disease associated with obesity and metabolic syndrome. The optimal management of chronic liver disease — including the selection and monitoring of antiviral therapy for hepatitis B and C, the management of autoimmune hepatitis and primary biliary cholangitis, the assessment and management of liver fibrosis and cirrhosis, and the prevention and treatment of cirrhosis complications including variceal bleeding, ascites, hepatic encephalopathy, and hepatorenal syndrome — requires a level of specialist hepatology expertise that is available at only a small number of dedicated liver disease centers. Dr. Shen's clinical practice at Renji Hospital — one of Shanghai's foremost hepatology centers — provides international patients with access to the full spectrum of modern hepatology care.
Hospital Affiliation: Department of Gastroenterology, Renji Hospital
Renji Hospital (仁济医院), affiliated with Shanghai Jiao Tong University School of Medicine, is one of Shanghai's largest and most prestigious academic medical centers, with particular national recognition in gastroenterology, hepatology, rheumatology, reproductive medicine, and liver transplantation. Its Department of Gastroenterology is one of the highest-volume and most academically productive gastroenterology and hepatology programs in China, managing a large caseload of chronic hepatitis B and C, autoimmune liver diseases, NAFLD, liver cirrhosis, and inflammatory bowel disease. The department's liver disease program is closely integrated with Renji Hospital's world-renowned liver transplantation program — led by Professor Xia Qiang — enabling seamless coordination of medical hepatology and surgical hepatology for patients with end-stage liver disease requiring transplantation evaluation.
Clinical Specialties: What Dr. Shen Xizhong Treats
- Chronic hepatitis B (CHB) — antiviral therapy initiation and agent selection (tenofovir alafenamide, tenofovir disoproxil fumarate, entecavir) based on HBV DNA, HBeAg status, ALT, and liver fibrosis stage; monitoring of antiviral therapy response including HBV DNA suppression, HBeAg seroconversion, and HBsAg decline; management of antiviral resistance; finite therapy strategies for HBeAg-positive CHB; novel therapy evaluation including HBV capsid assembly modulators and RNA interference agents in clinical trials; HCC surveillance coordination for cirrhotic and high-risk CHB patients
- Chronic hepatitis C (CHC) — direct-acting antiviral (DAA) therapy with sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and other pangenotypic regimens; SVR assessment and post-treatment monitoring; management of DAA-resistant HCV; HCC surveillance after SVR in cirrhotic patients; coordination with hematology for HCV-associated cryoglobulinemia and lymphoma
- Autoimmune liver diseases — autoimmune hepatitis (AIH) diagnosis using simplified diagnostic criteria and liver biopsy; induction of remission with corticosteroids and azathioprine; maintenance immunosuppression optimization; management of AIH overlap syndromes with PBC and PSC; primary biliary cholangitis (PBC) diagnosis and ursodeoxycholic acid (UDCA) therapy; obeticholic acid and fibrate therapy for UDCA non-responders; primary sclerosing cholangitis (PSC) management and cholangiocarcinoma surveillance; IgG4-related sclerosing cholangitis diagnosis and corticosteroid therapy
- Non-alcoholic fatty liver disease (NAFLD/MASLD) — non-invasive fibrosis assessment using FibroScan, FIB-4, and NAFLD fibrosis score; liver biopsy for staging in selected patients; lifestyle modification counseling; management of metabolic comorbidities (obesity, diabetes, dyslipidemia, hypertension); evaluation of novel pharmacological therapies for NASH/MASH including resmetirom, semaglutide, and other agents in clinical trials; HCC surveillance for NAFLD cirrhosis
- Liver cirrhosis and its complications — assessment of cirrhosis severity using Child-Pugh and MELD scores; variceal screening and prophylaxis with non-selective beta-blockers and endoscopic band ligation; management of acute variceal bleeding with terlipressin, octreotide, and endoscopic therapy; ascites management with diuretics, paracentesis, and TIPS; spontaneous bacterial peritonitis (SBP) prevention and treatment; hepatic encephalopathy management with lactulose and rifaximin; hepatorenal syndrome management; liver transplantation evaluation and referral coordination with Professor Xia Qiang's transplantation team
- Inflammatory bowel disease (IBD) — diagnosis and management of Crohn's disease and ulcerative colitis; biological therapy selection and optimization including anti-TNF agents, vedolizumab, ustekinumab, and JAK inhibitors; therapeutic drug monitoring; coordination with colorectal surgery for IBD surgical management
Why International Patients Choose Dr. Shen Xizhong and Renji Hospital
International patients — particularly those with chronic hepatitis B, autoimmune liver disease, or advanced liver cirrhosis — seek hepatology consultation with Dr. Shen Xizhong and Renji Hospital for reasons that reflect both the clinical depth of his hepatology expertise and the unique advantage of Renji Hospital's integrated medical hepatology and liver transplantation program.
For patients with chronic hepatitis B who are not yet on antiviral therapy or whose current therapy is not optimally suppressing HBV replication, Dr. Shen's expertise in antiviral therapy selection and monitoring — including the use of the most potent and resistance-barrier-high agents (tenofovir alafenamide, entecavir) and the evaluation of novel finite therapy strategies — provides access to optimal HBV management that minimizes the risk of cirrhosis progression and HCC development. For patients with autoimmune liver diseases — including AIH, PBC, and PSC — Dr. Shen's expertise in diagnosis and immunosuppressive management provides access to specialist care that is difficult to access outside major academic hepatology centers.
For patients with advanced liver cirrhosis and its complications, the integration of Dr. Shen's medical hepatology expertise with Renji Hospital's world-renowned liver transplantation program — led by Professor Xia Qiang, who has performed more pediatric liver transplantations than any surgeon in the world — provides a seamless pathway from medical management of cirrhosis complications to transplantation evaluation and listing for patients who progress to end-stage liver disease. The cost of hepatology consultation and treatment at Renji Hospital is substantially below that of equivalent care in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Shen Xizhong at Renji Hospital arranged through CMCS begin with a comprehensive review of all prior hepatology records — including liver function tests and bilirubin trend, HBV or HCV serology and viral load, autoimmune liver disease antibody panel (ANA, ASMA, AMA, LKM-1, SLA), liver imaging (ultrasound, CT, MRI), FibroScan results, prior liver biopsy pathology, prior antiviral or immunosuppressive therapy records, and the patient's liver disease history and relevant comorbidities. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation. Dr. Shen will assess the liver disease etiology, severity, and current management, outline the recommended diagnostic and therapeutic strategy, and coordinate transplantation evaluation where indicated. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Shen's team and the patient's home hepatologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking hepatology consultation with Dr. Shen Xizhong at Renji Hospital. Our services include priority consultation scheduling, certified medical record translation, coordination of liver imaging, FibroScan, and laboratory investigations, on-site interpretation, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
댓글 0개